Resection Versus Microwave Ablation for Resectable Colorectal Cancer Liver Metastases



Status:Terminated
Conditions:Colorectal Cancer, Liver Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - 75
Updated:8/1/2018
Start Date:August 2016
End Date:February 2018

Use our guide to learn which trials are right for you!

Prospective Randomized Comparison of Resection and Microwave Ablation for Resectable Colorectal Cancer Liver Metastases

This single-center, prospective, randomized clinical trial is designed to compare the
clinical characteristics and outcomes of hepatic resection and microwave ablation (MWA) to
determine the optimal operative intervention for the local treatment of resectable colorectal
cancer liver metastases. The primary aim of this study is to test the following hypothesis:
2-year local disease control is equivalent between patients receiving the experimental
therapy (MWA) and patients receiving the standard therapy (hepatic resection) as treatment
for colorectal cancer liver metastases determined to be resectable by radiographic imaging.
Secondarily, the investigators expect that 2-year intrahepatic (regional) and metastatic
disease recurrence rates are equivalent between the two treatment arms in this study.


Inclusion Criteria:

- Diagnosis of adenocarcinoma of the colon or rectum (diagnosed at the time of colon or
rectal resection or on endoscopic biopsy) with liver metastases (by liver biopsy or by
history of biopsy-proven colon/rectal cancer with characteristic imaging findings):

- Imaging showing typical features of colorectal cancer liver metastasis;

- Cytologic/histologic diagnosis of colorectal cancer or colorectal cancer liver
metastasis.

- No more than 3 hepatic metastatic lesions noted on preoperative imaging

- No lesion greater than 5 cm in maximal dimension

- Adequate clinical condition to undergo laparoscopic or robot-assisted laparoscopic
liver resection or microwave ablation as treatment for colorectal cancer liver
metastases

- Willing and able to give informed consent

Exclusion Criteria:

- Radiologic (computed tomography or magnetic resonance imaging) evidence of invasion
into major portal/hepatic venous branches and no extrahepatic metastases

- Evidence of recurrent disease adjacent to a previous ablation or resection site

- Severe renal dysfunction (creatinine clearance of <40 mL/min)

- Pregnant or nursing women
We found this trial at
1
site
1000 Blythe Blvd
Charlotte, North Carolina 28203
(704) 355-2000
Phone: 704-446-4838
?
mi
from
Charlotte, NC
Click here to add this to my saved trials